BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 33001846)

  • 1. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
    Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
    Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
    Rao D; Peitzsch M; Prejbisz A; Hanus K; Fassnacht M; Beuschlein F; Brugger C; Fliedner S; Langton K; Pamporaki C; Gudziol V; Stell A; Januszewicz A; Timmers HJLM; Lenders JWM; Eisenhofer G
    Eur J Endocrinol; 2017 Aug; 177(2):103-113. PubMed ID: 28476870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Laboratory evaluation of pheochromocytoma and paraganglioma.
    Eisenhofer G; Peitzsch M
    Clin Chem; 2014 Dec; 60(12):1486-99. PubMed ID: 25332315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma.
    Eisenhofer G; Lenders JW; Timmers H; Mannelli M; Grebe SK; Hofbauer LC; Bornstein SR; Tiebel O; Adams K; Bratslavsky G; Linehan WM; Pacak K
    Clin Chem; 2011 Mar; 57(3):411-20. PubMed ID: 21262951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines.
    Eisenhofer G; Lenders JW; Goldstein DS; Mannelli M; Csako G; Walther MM; Brouwers FM; Pacak K
    Clin Chem; 2005 Apr; 51(4):735-44. PubMed ID: 15718487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
    Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
    Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
    Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
    Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.
    Peitzsch M; Prejbisz A; Kroiß M; Beuschlein F; Arlt W; Januszewicz A; Siegert G; Eisenhofer G
    Ann Clin Biochem; 2013 Mar; 50(Pt 2):147-55. PubMed ID: 23512172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
    Peitzsch M; Kaden D; Pamporaki C; Langton K; Constantinescu G; Conrad C; Fliedner S; Sinnott RO; Prejbisz A; Därr R; Lenders JWM; Bursztyn M; Eisenhofer G
    Eur J Endocrinol; 2020 May; 182(5):499-509. PubMed ID: 32187575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of stability and interference for catecholamines and metanephrines, 3-methoxytyramine: key point of an accurate diagnosis for pheochromocytoma and paraganglioma.
    Wang K; Gao X; Zhang W; Sun N; Xie L; Cong H; Guo Y; Shi X; Zhou Z
    Scand J Clin Lab Invest; 2021 Nov; 81(7):564-572. PubMed ID: 34570657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of an enzyme immunoassay for plasma-free metanephrines in the diagnosis of catecholamine-secreting tumors.
    Procopiou M; Finney H; Akker SA; Chew SL; Drake WM; Burrin J; Grossman AB
    Eur J Endocrinol; 2009 Jul; 161(1):131-40. PubMed ID: 19383804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of plasma free metanephrines in diagnosis of pheochromocytomas and paragangliomas in the population of Asturias.
    Martínez-Morillo E; Valdés Gallego N; Eguia Ángeles E; Fernández Fernández JC; Prieto García B; Álvarez FV
    Endocrinol Diabetes Nutr (Engl Ed); 2019 May; 66(5):312-319. PubMed ID: 30391255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma.
    Bílek R; Zelinka T; Vlček P; Dušková J; Michalský D; Novák K; Václavíková E; Widimský J
    Physiol Res; 2017 Sep; 66(Suppl 3):S397-S408. PubMed ID: 28948824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated
    Eisenhofer G; Prejbisz A; Peitzsch M; Pamporaki C; Masjkur J; Rogowski-Lehmann N; Langton K; Tsourdi E; Pęczkowska M; Fliedner S; Deutschbein T; Megerle F; Timmers HJLM; Sinnott R; Beuschlein F; Fassnacht M; Januszewicz A; Lenders JWM
    Clin Chem; 2018 Nov; 64(11):1646-1656. PubMed ID: 30097498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma metanephrines measured by a commercial immunoassay and urinary catecholamines in the diagnosis of pheochromocytoma.
    Christensen TT; Frystyk J; Poulsen PL
    Scand J Clin Lab Invest; 2011 Dec; 71(8):695-700. PubMed ID: 22023043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of endocrine disease: Biochemical diagnosis of phaeochromocytoma and paraganglioma.
    van Berkel A; Lenders JW; Timmers HJ
    Eur J Endocrinol; 2014 Mar; 170(3):R109-19. PubMed ID: 24347425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection.
    Zuo M; Zhen Q; Zhang X; Zou W; Yang X; Tian G; Shi Z; Li Q; Ding M
    Clin Chim Acta; 2018 Mar; 478():82-89. PubMed ID: 29273559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-specific pediatric reference intervals for plasma free normetanephrine, metanephrine, 3-methoxytyramine and 3-O-methyldopa: Particular importance for early infancy.
    Peitzsch M; Mangelis A; Eisenhofer G; Huebner A
    Clin Chim Acta; 2019 Jul; 494():100-105. PubMed ID: 30904545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-centre study of the diagnostic performance of plasma metanephrines with seated sampling for the diagnosis of phaeochromocytoma/paraganglioma.
    Boot C; Toole B; Johnson SJ; Ball S; Neely D
    Ann Clin Biochem; 2017 Jan; 54(1):143-148. PubMed ID: 27170024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine.
    Eisenhofer G; Peitzsch M; Kaden D; Langton K; Mangelis A; Pamporaki C; Masjkur J; Geroula A; Kurlbaum M; Deutschbein T; Beuschlein F; Prejbisz A; Bornstein SR; Lenders JWM
    Clin Chim Acta; 2019 Mar; 490():46-54. PubMed ID: 30571948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.